Publications

  1. Xie H, Mahoney DW, Foote PH, Burger KN, Doering KA, Taylor WR, Then SS, Cao X, McGlinch M, Berger CK, Wu TT, Hubbard JM, Allawi HT, Kaiser MW, Lidgard GP, Ahlquist DA, Kisiel JB. Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence. Clin Cancer Res. 2021 Jan 1; 27 (1):141-149 Epub 2020 Oct 07
    View PubMed
  2. Francini E, Ou FS, Lazzi S, Petrioli R, Multari AG, Pesola G, Messuti L, Colombo E, Livellara V, Bazzurri S, Cherri S, Miano ST, Wolfe EG, Alberts SR, Hubbard JM, Yoon HH, Francini G. The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study. Transl Oncol. 2020 Dec 15; 14 (2):100973 [Epub ahead of print]
    View PubMed
  3. Xie H, Liu J, Yin J, Ogden JR, Mahipal A, McWilliams RR, Truty MJ, Bekaii-Saab TS, Petersen GM, Jatoi A, Hubbard JM, Ma WW. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Oncologist. 2020 Nov; 25 (11):e1681-e1690 Epub 2020 Aug 04
    View PubMed
  4. Xie H, Liu J, Ogden JR, Yin J, Jatoi A, Hubbard JM, McWilliams RR, Mahipal A, Petersen GM, Bekaii-Saab TS, Ma WW. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Am J Clin Oncol. 2020 Aug; 43 (8):586-590
    View PubMed
  5. Jethwa KR, Jang S, Mullikin TC, Harmsen WS, Petersen MM, Olivier KR, Park SS, Neben-Wittich MA, Hubbard JM, Sandhyavenu H, Whitaker TJ, Waltman LA, Kipp BR, Merrell KW, Haddock MG, Hallemeier CL. Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer. Radiother Oncol. 2020 May; 146:29-36 Epub 2020 Feb 27
    View PubMed
  6. Sonbol MB, Mountjoy LJ, Firwana B, Liu AJ, Almader-Douglas D, Mody K, Hubbard J, Borad M, Ahn DH, Murad MH, Bekaii-Saab T. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. JAMA Oncol. 2020 Mar 1; 6 (3):e194489 Epub 2020 Mar 12
    View PubMed
  7. Adjei A, Buckner JC, Cathcart-Rake E, Chen H, Cohen HJ, Dao D, De Luca JE, Feliciano J, Freedman RA, Goldberg RM, Hopkins J, Hubbard J, Jatoi A, Karuturi M, Kemeny M, Kimmick GG, Klepin HD, Krok-Schoen JL, Lafky JM, Le-Rademacher JG, Li D, Lichtman SM, Maggiore R, Mandelblatt J, Morrison VA, Muss HB, Ojelabi MO, Sedrak MS, Subbiah N, Sun V, Tuttle S, VanderWalde N, Wildes T, Wong ML, Woyach J, Alliance Cancer in the Older Adult Committee:. Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology. J Geriatr Oncol. 2020 Mar; 11 (2):179-183 Epub 2019 June 11
    View PubMed
  8. Xie H, Lafky JM, Morlan BW, Stella PJ, Dakhil SR, Gross GG, Loui WS, Hubbard JM, Alberts SR, Grothey A. Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). Ther Adv Med Oncol. 2020; 12:1758835920910913 Epub 2020 Mar 06
    View PubMed
  9. Jin Z, Hubbard JM. Optimizing biologic sequencing in metastatic colorectal cancer: first line and beyond. Curr Oncol. 2019 Nov; 26 (Suppl 1):S33-S42 Epub 2019 Nov 01
    View PubMed
  10. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming DA, Garrido-Laguna I, Grem JL, Hoffe SE, Hubbard J, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen KS, Saltz LB, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gregory KM, Gurski LA. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Sep 1; 17 (9):1109-1133
    View PubMed
  11. Sonbol MB, Benkhadra R, Wang Z, Firwana B, Walden DJ, Mody K, Hubbard JM, Murad MH, Ahn DH, Bekaii-Saab T. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. Oncologist. 2019 Sep; 24 (9):1174-1179 Epub 2019 June 04
    View PubMed
  12. Chakrabarti S, Huebner LJ, Finnes HD, Muranyi A, Clements J, Singh S, Hubbard JM, McWilliams RR, Shanmugam K, Sinicrope FA. Intratumoral cd3(+) and cd8(+) t-cell densities in patients with dna mismatch repair-deficient metastatic colorectal cancer receiving programmed cell death-1 blockade JCO Precision Oncology. 2019 Jun 28; 3:1-7
  13. Houts AC, Ogale S, Zafar Y, Hubbard JM, Satram-Hoang S, Sommer N, Walker MS. Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings. J Gastrointest Cancer. 2019 Mar; 50 (1):16-22
    View PubMed
  14. Kommalapati A, Tella SH, Goyal G, Borad M, Alberts SR, Roberts L, Hubbard JM, Durgin L, Cleary S, Mahipal A. Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. HPB (Oxford). 2019 Mar; 21 (3):379-386 Epub 2018 Sept 25
    View PubMed
  15. Duma N, Kothadia SM, Azam TU, Yadav S, Paludo J, Vera Aguilera J, Gonzalez Velez M, Halfdanarson TR, Molina JR, Hubbard JM, Go RS, Mansfield AS, Adjei AA. Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. Oncologist. 2019 Jan; 24 (1):96-102 Epub 2018 Nov 09
    View PubMed
  16. Ogden JR, Xie H, Ma WW, Hubbard JM. The Management of Older Adults with Pancreatic Adenocarcinoma. Geriatrics (Basel). 2018 Nov 26; 3 (4)
    View PubMed
  17. Pant S, Hubbard J, Martinelli E, Bekaii-Saab T. Clinical update on K-Ras targeted therapy in gastrointestinal cancers. Crit Rev Oncol Hematol. 2018 Oct; 130:78-91 Epub 2018 Aug 02
    View PubMed
  18. Jin Z, Sanhueza CT, Johnson B, Nagorney DM, Larson DW, Mara KC, Harmsen WC, Smyrk TC, Grothey A, Hubbard JM. Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience. Oncologist. 2018 Sep; 23 (9):1083-1091 Epub 2018 Apr 19
    View PubMed
  19. Mislang AR, Di Donato S, Hubbard J, Krishna L, Mottino G, Bozzetti F, Biganzoli L. Nutritional management of older adults with gastrointestinal cancers: An International Society of Geriatric Oncology (SIOG) review paper. J Geriatr Oncol. 2018 Jul; 9 (4):382-392 Epub 2018 Feb 01
    View PubMed
  20. McCleary NJ, Hubbard J, Mahoney MR, Meyerhardt JA, Sargent D, Venook A, Grothey A. Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol. 2018 Jan; 9 (1):24-31 Epub 2017 Sept 13
    View PubMed
  21. Duma N, Vera Aguilera J, Paludo J, Haddox CL, Gonzalez Velez M, Wang Y, Leventakos K, Hubbard JM, Mansfield AS, Go RS, Adjei AA. Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. J Oncol Pract. 2018 Jan; 14 (1):e1-e10 Epub 2017 Nov 03
    View PubMed
  22. Dose AM, Hubbard JM, Mansfield AS, McCabe PJ, Krecke CA, Sloan JA. Feasibility and Acceptability of a Dignity Therapy/Life Plan Intervention for Patients With Advanced Cancer. Oncol Nurs Forum. 2017 Sep 1; 44 (5):E194-E202
    View PubMed
  23. Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A. (Non-V600) BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017 Aug 10; 35 (23):2624-2630 Epub 2017 May 09
    View PubMed
  24. Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, Frankel W, Collisson E, Koay EJ, Hubbard JM, Leenstra JL, Meyerhardt J, O'Reilly E, Alliance for Clinical Trials on Oncology. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017 Jul 27; 17 (1):505 Epub 2017 July 27
    View PubMed
  25. Hubbard JM, Grothey A. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. Drugs. 2017 Jul; 77 (10):1091-1103
    View PubMed
  26. Zhang BY, Jones JC, Briggler AM, Hubbard JM, Kipp BR, Sargent DJ, Dixon JG, Grothey A. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2017 Jun; 16 (2):124-128 Epub 2016 Sept 17
    View PubMed
  27. Bendell J, Hubbard J, O'Neil BH, Jonker D, Starodub A, Peyton J, Pitot H, Halfdanarson T, Nadeau B, Zubkus J, Adesunloye B, Edenfield J, Li YZ, Li W, Grothey A, Borodyansky L, Li CJ. Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts). Ann Oncol. 2017 Jun; 28 Suppl 3:iii150-iii151
    View PubMed
  28. Hubbard JM, Mahoney MR, Loui WS, Roberts LR, Smyrk TC, Gatalica Z, Borad M, Kumar S, Alberts SR. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol. 2017 Apr; 12 (2):201-209
    View PubMed
  29. Childs DS, Jacobson AC, Mitchell JL, Hubbard JM, Yoon HH, Finnes H, Grothey A, Jatoi A. Prescriber adherence to antiemetic guidelines with the new agent trifuridine-tipiracil Journal of Community and Supportive Oncology. 2017; 15: (3)e142-6.
  30. VanderWalde N, Jagsi R, Dotan E, Baumgartner J, Browner IS, Burhenn P, Cohen HJ, Edil BH, Edwards B, Extermann M, Ganti AK, Gross C, Hubbard J, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Shepard D, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Wildes T, Bergman MA, Sundar H, Hurria A. NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. J Natl Compr Canc Netw. 2016 Nov; 14 (11):1357-1370
    View PubMed
  31. Hubbard JM, Kim G, Borad MJ, Johnson E, Qin R, Lensing J, Puttabasavaiah S, Wright J, Erlichman C, Grothey A. Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Invest New Drugs. 2016 Feb; 34 (1):96-103 Epub 2015 Nov 18
    View PubMed
  32. Hubbard JM. Management of Colorectal Cancer in Older Adults. Clin Geriatr Med. 2016 Feb; 32: (1)97-111.
    View PubMed
  33. Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, Van Cutsem E, Argiles G, Adenis A, Ychou M, Barone C, Bouche O, Peeters M, Humblet Y, Mineur L, Sobrero AF, Hubbard JM, Cremolini C, Prenen H, Tabernero J, Jarraya H, Mazard T, Deguelte-Lardiere S, Papadimitriou K, Van den Eynde M, Pastorino A, Redaelli D, Bencardino K, Funaioli C, Amatu A, Carlo-Stella G, Torri V, Sartore-Bianchi A, Vanzulli A, Siena S. Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study). ESMO Open. 2016; 1 (6):e000111 Epub 2017 Feb 13
    View PubMed
  34. Thanarajasingam G, Hubbard JM, Sloan JA, Grothey A. The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. J Natl Cancer Inst. 2015 Oct; 107: (10).
    View PubMed
  35. Pachman DR, Ruddy K, Sangaralingham LR, Grothey A, Shah ND, Beutler AS, Hubbard JM, Loprinzi CL. Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice. J Natl Compr Canc Netw. 2015 Sep; 13 (9):1097-101
    View PubMed
  36. Hubbard JM, Jatoi A. Incorporating biomarkers of frailty and senescence in cancer therapeutic trials. J Gerontol A Biol Sci Med Sci. 2015 Jun; 70(6):722-8. Epub 2014 Apr 26.
    View PubMed
  37. Hubbard JM, Grothey A. Colorectal cancer in 2014: progress in defining first-line and maintenance therapies. Nat Rev Clin Oncol. 2015 Feb; 12 (2):73-4 Epub 2015 Jan 06
    View PubMed
  38. Leal AD, Hubbard J, Sargent D, Grothey A. New adjuvant trial designs in colon cancer Current Colorectal Cancer Reports. 2015; 11: (6)326-34.
  39. Kasi PM, Thanarajasingam G, Finnes HD, Villasboas Bisneto JC, Hubbard JM, Grothey A. Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer. Case Rep Oncol Med. 2015; 2015:420159 Epub 2015 May 21
    View PubMed
  40. Hubbard JM, Grothey A. Colorectal cancer in 2014 : Progress in defining first-line and maintenance therapies Nature Reviews Gastroenterology and Hepatology. 2015; 12: (1)19-20.
  41. Hubbard JM, Cohen HJ, Muss HB. Incorporating biomarkers into cancer and aging research. J Clin Oncol. 2014 Aug 20; 32 (24):2611-6 Epub 2014 July 28
    View PubMed
  42. Hubbard JM, Grothey AF, McWilliams RR, Buckner JC, Sloan JA. Physician perspective on incorporation of oncology patient quality-of-life, fatigue, and pain assessment into clinical practice. J Oncol Pract. 2014 Jul; 10 (4):248-53 Epub 2014 Mar 25
    View PubMed
  43. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, Alliance for Clinical Trials in Oncology. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014 Jul; 106 (7) Epub 2014 June 12
    View PubMed
  44. Sridharan M, Hubbard JM, Grothey A. Colorectal cancer: how emerging molecular understanding affects treatment decisions. Oncology (Williston Park). 2014 Feb; 28 (2):110-8
    View PubMed
  45. Lapid MI, Atherton PJ, Clark MM, Kung S, Richardson JW, Cheville AL, Dyrbye LN, Hubbard JM, Piderman KM, Shanafelt TD, Sloan JA, West CP, Schott DK, Rummans TA. Geriatric and non-geriatric cancer caregivers: Perceived benefits of technology. Gerontechnology. 2014; 13(2):231.
  46. Hubbard JM, Grothey A. Adolescent and young adult colorectal cancer. J Natl Compr Canc Netw. 2013 Oct 1; 11 (10):1219-25
    View PubMed
  47. Hubbard JM, Alberts SR. Alternate dosing of cetuximab for patients with metastatic colorectal cancer. Gastrointest Cancer Res. 2013 Mar; 6 (2):47-55
    View PubMed
  48. Hubbard J, Thomas DM, Yothers G, Green E, Blanke C, O'Connell MJ, Labianca R, Shi Q, Bleyer A, de Gramont A, Sargent D. Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. J Clin Oncol. 2012 Jul 1; 30 (19):2334-9 Epub 2012 May 21
    View PubMed
  49. Lewis M, Hubbard J. Treatment of liver-limited disease from colorectal cancer. Journal of Interventional Oncology. March 2012; 2(1):15-24.
  50. Hubbard J, Erlichman C, Toft DO, Qin R, Stensgard BA, Felten S, Ten Eyck C, Batzel G, Ivy SP, Haluska P. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest New Drugs. 2011 Jun; 29 (3):473-80 Epub 2010 Jan 15
    View PubMed
  51. Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol. 2011; 5:89-99 Epub 2011 Apr 25
    View PubMed
  52. Hubbard J, Grothey A. Reduced chemotherapy duration: A good idea? Current Colorectal Cancer Reports. 2011; 7(3):241-5.
  53. Lewis MA, Hubbard J. Multimodal liver-directed management of neuroendocrine hepatic metastases. Int J Hepatol. 2011; 2011:452343 Epub 2011 Oct 29
    View PubMed
  54. Hubbard J, Grothey A. Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol. 2010 Jul; 22 (4):374-80
    View PubMed
  55. Hubbard JM, Alberts SR. Treatment of liver-limited metastatic colorectal cancer. Cancer J. 2010 May-Jun; 16(3):235-40.
    View PubMed
  56. de Gramont, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2010 Jan 20; 28(3):460-5. Epub 2009 Dec 14.
    View PubMed
  57. Hubbard J, Grothey A. Strategies for managing chemotherapy-induced sensory neuropathy. Current Colorectal Cancer Reports. 2010; 6(3):126-32.
  58. Hubbard J, Sargent D. Evidence for Cure by Adjuvant Chemotherapy in Colorectal Cancer Review. American Journal of Hematology/Oncology. 2009; 8(9):419-24.